Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Lung Cancer
81%
Tumor
56%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
41%
Overall Survival
30%
Chemotherapy
29%
Dendritic Cells
23%
Small Cell Lung Cancer
21%
Insulin-like
19%
Insulin-like Growth Factor 1 Receptor (IGF1R)
19%
Growth Factors
18%
Immune Checkpoint Inhibitors
17%
Programmed Death-ligand 1 (PD-L1)
15%
Adenovirus
15%
Non-small Cell Lung Cancer Patients
15%
Vascular Endothelial Growth Factor
15%
Tumor Cells
15%
Erlotinib
14%
Paclitaxel
14%
In Cancer
14%
International Association for the Study of Lung Cancer (IASLC)
13%
Resectable Lung Cancer
12%
Lung Cancer Treatment
12%
Confidence Interval
12%
Nivolumab Plus Ipilimumab
12%
CheckMate
12%
Metastatic Non-small Cell Lung Cancer
12%
Hazard Ratio
11%
Phase II Trial
11%
Clinical Trials
11%
Mutant p53
10%
Tumor Growth
10%
EGFR mutation
10%
Continuous Infusion
10%
Lung Adenocarcinoma
10%
Cancer Patients
10%
Radiation Therapy
10%
Targeted Therapy
10%
Human Lung Cancer
9%
Lung Cancer Patients
9%
NOTCH3
9%
Phase I Study
9%
Lung Cancer Cell Lines
8%
Clinical Outcomes
8%
TP53 mutation
8%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
8%
Cytotoxic T Lymphocytes
8%
KRAS mutation
8%
Locally Advanced
8%
United States
8%
Medicine and Dentistry
Non Small Cell Lung Cancer
87%
Lung Cancer
87%
Neoplasm
53%
Malignant Neoplasm
32%
Overall Survival
30%
Immunotherapy
21%
Diseases
21%
Epidermal Growth Factor Receptor
19%
Non-Small Cell Lung Cancer
18%
Small Cell Lung Cancer
18%
Nivolumab
16%
Biological Marker
15%
Protein P53
13%
Ipilimumab
13%
Targeted Therapy
12%
Sodium Fluoride
11%
Programmed Death 1 Ligand 1
11%
Proteomics
10%
Lung Adenocarcinoma
10%
Lung
10%
Immune Checkpoint Inhibitor
9%
Dendritic Cell
9%
Radiation Therapy
8%
Hazard Ratio
8%
Notch
8%
Arm
8%
Cancer Cell
8%
Progression Free Survival
7%
Chemoradiotherapy
7%
Cancer
7%
Adverse Event
7%
Carcinogenesis
6%
Adenoviridae
6%
Metastatic Carcinoma
6%
Lung Cancer Cell Line
6%
Brain Metastasis
6%
Messenger RNA
6%
Health Care Cost
6%
Somatomedin C Receptor
6%
Atezolizumab
6%
Oncology
6%
Cancer Staging
5%
Clinical Trial
5%
T Cell
5%
Immune Response
5%
Receptor
5%
Recurrent Disease
5%
Exon
5%
Cell Line
5%
Primary Tumor
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
87%
Lung Cancer
66%
Neoplasm
53%
Malignant Neoplasm
34%
Chemotherapy
34%
Overall Survival
28%
Somatomedin C Receptor
20%
Diseases
20%
Immunotherapy
19%
Epidermal Growth Factor Receptor
18%
Paclitaxel
16%
Somatomedin
16%
Protein P53
14%
Small Cell Lung Cancer
14%
Nivolumab
13%
Immune Checkpoint Inhibitor
13%
Biological Marker
13%
Adenoviridae
12%
Adverse Event
12%
Erlotinib
11%
Receptor
11%
Ipilimumab
10%
Chemoradiation Therapy
10%
Programmed Death 1 Ligand 1
9%
Vasculotropin
9%
Sodium Fluoride
9%
Progression Free Survival
8%
Clinical Trial
8%
Carboplatin
7%
Digestive System Cancer
7%
Bevacizumab
6%
Docetaxel
6%
Epidermal Growth Factor Receptor Kinase Inhibitor
6%
Protein Tyrosine Kinase Inhibitor
6%
Solid Malignant Neoplasm
5%
Combination Therapy
5%
Tumor Growth
5%
Carcinogenesis
5%
